---
title: Personalize brain stimulation for movement
nct_id: NCT07398157
phase: NA
status: RECRUITING
sponsor: University of California, San Francisco
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07398157"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07398157"
last_fetched: "2026-05-10T14:06:12.916Z"
source: "Parkinson's Pathways (curated)"
---
# Personalize brain stimulation for movement

**Goal (in five words):** Personalize brain stimulation for movement

**Official Title:** Subgaleal Cortical Electrodes in Patients With Parkinson's Disease Undergoing Deep-brain Stimulation Therapy for Sensing and Adaptive Deep-brain Stimulation Over a 24-hour Period.

**Trial ID:** [NCT07398157](https://clinicaltrials.gov/study/NCT07398157)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University of California, San Francisco
- **Target Enrollment:** 24 participants
- **Start Date:** 2026-04-09
- **Completion Date:** 2029-11-30
- **Conditions:** PD - Parkinson's Disease
- **Interventions:** Medtronic Percept Deep Brain Stimulation (cDBS), Medtronic Percept Deep Brain Stimulation (daytime aDBS), Medtronic Percept Deep Brain Stimulation (nighttime aDBS)
- **Intervention Types:** DEVICE

## Summary For Families

They are testing whether adding thin sensing electrodes under the scalp can let deep-brain stimulation adjust itself over a full 24 hours to reduce daytime off periods, troublesome dyskinesias, and sleep-related problems. The Medtronic Percept system records cortical rhythms from the subgaleal electrodes and runs closed-loop adaptive DBS that increases stimulation when brain signals predict an off state or motor symptoms and reduces stimulation during good on periods or sleep, so it is designed to work alongside levodopa rather than replace it. Adults 25 to 75 with idiopathic Parkinson's who are DBS candidates, have motor fluctuations despite optimized medications with at least two hours per day of off time or on time with dyskinesias, a normal brain MRI, and preserved cognition (MoCA 24 or higher) are being recruited. People with major medical or psychiatric risks, MR-incompatible implants, or other surgical contraindications are excluded, and about 24 participants will be enrolled.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion criteria

1. Age 25-75.
2. Diagnosis of idiopathic PD.
3. Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist (Dr. Bledsoe).
4. Patient has requested surgical intervention with deep brain stimulation for their disorder or previous enrollment in sponsored IDE (G220241) to use Percept PC wired to subgaleal sensing, if patients have ongoing daytime fluctuations or sleep dysfunction despite cDBS optimization.
5. Normal preoperative brain MRI.
6. Absence of significant cognitive impairment (score of 24 or greater on the Montreal Cognitive Assessment (MoCA).
7. Signed informed consent.
8. Motor UPDRS-III off medication score 25 to 65 and a \>35% improvement with levodopa, predominant rigid/bradykinetic symptoms (ratio of off-medication UPDRS-III limb rigidity/bradykinesia scores to limb tremor scores of \>1.2).
9. Motor fluctuations despite optimized medical therapy with at least 2 hours per day of either "off" time, or "on" with dyskinesias.
10. Ability to comply with study follow-up visits for brain recording, testing of closed-loop stimulation, and clinical assessment.

Exclusion criteria

1. Coagulopathy, uncontrolled hypertension, heart disease, or other medical condition considered to place the patient at elevated risk for surgical complications.
2. Patient meets criteria for a psychogenic movement disorder.
3. Pregnancy: all women of childbearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure.
4. Significant untreated depression (BDI-II score \>20) History of suicidal attempt or active suicidal ideation (Yes to #2-5 on C-SSRS).
5. Any personality or mood symptoms that study personnel believe will interfere with study requirements.
6. Patient who requires electroconvulsive therapy, repetitive transcranial magnetic stimulation, or diathermy, implanted neurostimulators and MR-incompatible metallic implants, previous craniotomy on the side of the intended subgaleal implant, and drug or alcohol abuse.
7. Patients who experience adverse effects that are undesirable and detrimental to the health of subjects from DBS or other similar neurostimulators
```

## Locations (1)

- University of California San Francisco, San Francisco, California, United States _(37.7749, -122.4194)_
  - Sarah Wang, PhD — (CONTACT) — 415-353-7885 — Sarah.Wang@ucsf.edu

## Central Contacts

- Clinical Research Coordinator — (CONTACT) — 5175152739 — sebastian.liu@ucsf.edu
- Research Manager — (CONTACT) — sarah.wang@ucsf.edu

---

*Canonical: https://parkinsonspathways.com/trial/NCT07398157*  
*HTML version: https://parkinsonspathways.com/trial/NCT07398157*  
*Source data: https://clinicaltrials.gov/study/NCT07398157*